DIJON, France-- (BUSINESS WIRE)--Regulatory News: “These complete Phase 1 results confirm and validate OPM-101 as a highly specific, effective and well-tolerated inhibitor of the RIPK2 immune ...

These results, when taken together with previous structural biology studies on RIPK2, offer valuable information for the development of therapeutics to treat inflammatory bowel diseases.

(Heading image: Binding of the Rab5 (GTP) to EEA1 triggers a transition of the EEA1 molecule from a rigid, extended state to a more flexible, collapsed state. (Credit: Anupam Singh et al., 2023) ) ...

Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024 ...

Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics said, “Dosing of the first patient in AC-101’s Phase 1b study represents a significant step towards advancing this novel oral therapeutic ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the ...

Poster: MP119 Title: Unveiling the strong safety profile and high target engagement of OPM-101, a first-in-class orally available RIPK2 inhibitor, in a phase 1 clinical trial in healthy volunteers ...

Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics said, "We are thrilled to receive FDA clearance of IND for AC-101, which is one of the leading RIPK2 inhibitors worldwide.

Chen, Y., et al. (2025). CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury. Acta Pharmaceutica Sinica B ...